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Further Discussion on the Treatment of Hypertension 
 
1. Hermida RC, Ayala DE, Mojón A, et al. Influence of circadian time of 
hypertension treatment on cardiovascular risk: results of the MAPEC 
study. Chronobiol Int. 2010;27:1629–1651. 
 
Background: 
A patient’s blood pressure changes throughout the day, in sync with the rest-activity cycle. The 
body’s circadian rhythm contributes to fluctuation in blood pressure and affects the body’s 
response to antihypertensive medications. Traditionally, blood pressure medications are 
prescribed to be taken in the morning. Patients on more than 1 blood pressure medication 
usually take their medications all at once.  Recent studies have shown that sleep time blood 
pressure may be a more important factor than daytime blood pressure readings in fatal and 
nonfatal cardiovascular disease events.  
Study type:  
Randomized controlled trial, results evaluated from Ambulatory Blood Pressure Monitoring for 
Prediction of Cardiovascular Events Study (MAPEC)  
2201 subjects diagnosed with untreated or resistant hypertension (awake BP mean greater than 
or equal to 135/85, asleep BP mean greater than or equal to 120/70), 1109 patients allocated to 
treatment in the morning, 1092 allocated to take >=1 medication at bedtime. Blood pressure was 
measured for 48 hours annually for a mean follow up of 5.6 years 
Results:  
-Differences between groups for mean BP while awake were not significant p=0.546 
-Proportion of patients with non dipper blood pressure was lower in bedtime group than morning 
group 34% versus 62% p<0.001 
-Relative risk of major CVD events (death, MI, ischemic stroke, hemorrhagic stroke) 0.39 
p<0.001 when greater than or equal to one medication at bedtime was taken versus all 
medications ingested in the morning  
Conclusions: 
-Patients experienced better blood pressure control during sleep while taking at least one or 
more blood pressure medications at bedtime 
-Major CVD events were lower in patients who took one or more of their blood pressure 
medications at bedtime NNT 30 over 5.6 years 
-In comparison- patients with moderate to severe hypertension (SBP > 160), NNT for a patient 
taking low dose thiazide diuretics for 5 years was 20 in the primary prevention of cardiovascular 
events 1 
 
2. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug 
class on interindividual variation in blood pressure and risk of stroke: a 
systematic review and meta-analysis. Lancet. 2010 Mar 13;375(9718):906-15. 
 
Background:  
Studies show an increase in 20 mm Hg of SBP doubles the risk of stroke in individuals from 40-69 
years of age. All hypertensive drugs have been shown to decrease stroke and cardiovascular 
events with decreasing mean blood pressure. However, class variations may exist. Previous 
studies showed CCB decreased stroke risk more than what is expected from simply decreasing 
blood pressure, hence there may be more to benefit from certain antihypertensive agents than 
just the lowering of mean blood pressure. 
Study type:  
Meta-analysis and systematic review 
Study evaluated 398 RCT which studied changes in interindividual variance in blood pressure at 
the highest dose of different antihypertensive drugs with mean SBP measured at one year in 
each study. Eight drug classes were evaluated: dihydropyridine CCB, non-dihydropyridine CCB, 
thiazide and thiazide like diuretics, ACEi, beta blockers, ARB, alpha1 blockers 
Results:  
-Interindividual variation in SBP was decreased by CCB (VR 0.81, p<0.0001), non-loop diuretics 
(0.97, p= 0.007), but increased by ACEi (1.08, p=0.008), ARB (1.16, p=0.0002), beta blockers 
(1.17, p=0.0007) (each drug class was compared to all other drug classes) 
-A significant reduction in stroke with lower SD for systolic blood pressure was shown p=0.012 
Conclusions:  
-CCB and thiazide diuretics decrease interindividual variation of blood pressure  
-Blood pressure medications which decreased interindividual variation showed statistically 
significant reduction in stroke risk 
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